Imperial College London


Faculty of MedicineDepartment of Brain Sciences

Professor of Neurology and Genomic Medicine



m.johnson Website




E419Burlington DanesHammersmith Campus






BibTex format

author = {Johnson, MR and Kaminski, RM},
doi = {10.1016/j.neuropharm.2019.107868},
journal = {Neuropharmacology},
pages = {1--15},
title = {A systems-level framework for anti-epilepsy drug discovery},
url = {},
volume = {170},
year = {2019}

RIS format (EndNote, RefMan)

AB - Modern anti-seizure drug development yielded benefits in terms of improved pharmacokinetics, safety and tolerability profiles, but offered no advances in efficacy compared to previous older generations of anti-seizure drugs. Despite significant advances in our understanding of the genetic bases to epilepsy, and a welcome renewed interest on the severe monogenic epilepsies, modern genetics has yet to directly inform more effective or disease-modifying anti-seizure drugs. Here, we describe a new approach to the identification of novel disease modifying anti-epilepsy drugs. The systems genetics approach aims to first identify pathophysiological mechanisms by integrating polygenic risk with cellular gene expression profiles and then to relate these molecular mechanisms to druggable targets using a gene regulatory (regulome) framework. The approach offers an exciting and flexible framework for future drug discovery in epilepsy, and is applicable to any disease for which appropriate cell-type and disease-context specific data exist.
AU - Johnson,MR
AU - Kaminski,RM
DO - 10.1016/j.neuropharm.2019.107868
EP - 15
PY - 2019///
SN - 0028-3908
SP - 1
TI - A systems-level framework for anti-epilepsy drug discovery
T2 - Neuropharmacology
UR -
UR -
UR -
UR -
VL - 170
ER -